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Summary --In daily sessions of a two-lever. discrete-trial, food-reinforced procedure, rhesus monkeys 
were trained to discriminate between subcutaneous injections of ketamine (1.0 or 1.8 mg/kg) and control 
injections. In tests of stimulus generalization, cumulative doses of drugs were administered in single 
sessions and either control- or ketamine-appropriate responding produced food. Ketamine (1.8 and 
3.2 m&/kg) and phencyclidine (0.32 mg/kg) produced an average of more than 90:; ketamine-appropriate 
responding. In contrast. d-amphetamine, atropine. chlorpromazine, codeine, diazepam and quipazine. 
tested at doses up to and including those that markedly reduced response rates, produced exclusively 
control-appropriate responding. Dose-related ketamine-appropriate responding was produced by each 
of ten I-phenylcyclohexylamines. the potencies of which varied with the length. electronegativity, and 
number of N-alkyl chains present. The most potent analog of phencyclidine, N-ethyl-l-phenylcyclohexyl- 
amine, was approximately equipotent with phencyclidine. These data are consistent with previous 
reports that the discriminative stimulus effects produced by phencychdine are representative of a unique 
class of drugs. and that alkyl substitutions in the region of the piperidine ring alter the potency, but not 
the characteristic pharmacological activity. of the resulting analogs. The potencies of some of these 
analogs compared to phencyclidine in rhesus monkeys. however, differed from their relative potencies in 
rodents. Thus. there appear to be species differences in the role of the nitrogen pharmacophore of these 
compounds in producing phencyclidine-like behavioral effects. 
Developed originally as an anesthetic, phencyclidine 
(PCP) was found to offer several advantages, such as 
a lack of cardiovascular and respiratory depression at 
anesthetic doses in laboratory animals (Chen, 1958) 
and in man (Chen, Ensor. Russel and Bohner, 1959). 
Upon emergence from anesthesia, however, phencyc- 
lidine was found to produce a dissociative state char- 
acterized by feelings of unreality, anxiety and deperson- 
alization (Greifenstein, DeVault, Yoshitake and 
Gajewski. 1958). Additionally, phencyclidine produces 
subjective and behavioral effects which more closely 
resemble the primary symptoms of schizophrenia 
than do the effects produced by other psychotomime- 
tic agents. such as D-lysergic acid diethylamide (LSD) 
(Cohen. Rosenbaum. Luby. Gottlieb and Yelen, 1959; 
Luby, Cohen, Rosenbaum. Gottlieb and Kelley, 1959; 
Cohen Rosenbaum. Luby and Gottlieb. 1962). The 
magnitude of these effects and the frequency with 
which they occur have prevented phencyclidine from 
being used for anesthesia in humans. Ketamine 
is a less potent and shorter-acting analog of phencyc- 
lidine (McCarthy, Chen, Kemp and Ensor. 1965) that 
continues to be used clinically, although it is not en- 
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tirely free of dissociative activity (Domino, Chodoff 
and Corssen, 1965). Despite its presumably un- 
pleasant effects, phencyclidine has emerged as a drug 
of widespread abuse (Peterson and Stillman, 1978). 
and ketamine as well as several other analogs of 
phencyclidine have been identified in illicit samples, 
suggesting that they may share abuse liability with 
phencyclidine (Shulgin and MacLean, 1976). 
Similarities between the discriminative stimulus 
effects of phencyclidine and ketamine have been dem- 
onstrated in a number of species, including rats 
(Overton, 1975; Jirbe, Johannson and Henriksson, 
1975; Poling, White and Appel, 1979; Holtzman, 
1980; Shannon, 1981), pigeons (Herling, Coale, Hein, 
Winger and Woods, 1981) and squirrel monkeys 
(Brady and Balster, 1981). A variety of structural ana- 
logs of phencyclidine also share discriminative effects 
with the parent compound (Shannon, 1981; Brady 
and Balster, 1981), while a number of psychoactive 
drugs from various pharmacological classes (e.g. LSD, 
d-amphetamine, pentobarbital and tetrahydrocanna- 
binol) do not (Poling et al., 1979; Shannon, 1981). 
These data suggest that phencyclidine and its analogs 
act through common neuropharmacological mechan- 
isms that are distinct from those of other psychoactive 
drugs. Evidence for biologically significant receptor 
sites for phencyclidine has recently been provided by 
reports of the displacement of [ 3H]phencyclidine 
from rat and pigeon brain membranes by appropriate 
concentrations of drugs which produce behavioral 
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effects resembling those of phencyclidine (Vincent, 
Kartalovski. Geneste, Kamenka and Lazdunski, 1979: 
Zukin and Zukin. 1979, 1981; Hampton Medzih- 
radsky and Woods. 1980. 1982). 
The present experiment was designed. firstly, to 
demonstrate that phencyclidine and ketamine share 
discriminative stimulus effects in another species. the 
rhesus monkey. Because the behavioral effects of 
phencyclidine in man more closely resemble its effects 
in nonhuman primates than in rodents or avian spe- 
cies (Chen, 1958), the actions of phencyclidine and 
related drugs in the rhesus monkey may be more 
closely related to their pharmacology in man. 
Secondly, the pharmacological specificity of the dis- 
criminative effects of ketamine was investigated by 
evaluating a number of psychoactive agents for the 
ability to engender responding appropriate for 
ketamine. Finally, a series of structural analogs of 
phencyclidine was evaluated for the ability to produce 
ketamine-like discriminative effects. The analogs of 
phencyclidine tested in this experiment contained 
various N-alkyl substitutions in place of the piper- 
idine ring of phencyclidine and thus provided a basis 
for systematically evaluating structureeactivity re- 
lationships at the nitrogen pharmacophore. In 
rodents, alkyl substitutions in this part of the mol- 
ecule alter the potency but not the pharmacological 
activity of analogs of phencyclidine (Jasinski. Shan- 
non. Cone. Vaupel. Risner. McQuinn. Su and Pick- 
worth, 1981; Shannon, 1981; Shannon and DeGre- 
gorio. 1981). In the present experiment, the generali- 
zation of this finding to the rhesus monkey was inves- 
tigated. 
METHODS 
Three rhesus monkeys (Mactrc~ rntrlnrtu) were 
trained to lever press with food reinforcement (Ferster 
and Skinner. 1957) and were maintained at weights of 
7.G9.0 kg, which represented approx. 80”” of their 
free-feeding weights. Each monkey was housed indi- 
vidually and was given sufficient food (Purina High 
Protein Monkey Chow, No. 5045. Ralston-Purina 
Co.. St Louis. MO) following the daily experimental 
sessions to maintain these reduced weights. Water 
was freely available in the home cages and fresh fruit 
was provided several times a week. Isoniazid (40 mg) 
was administered daily on a sugar cube, 
Each monkey (754, 794 and 808) had a complex 
experimental and drug history; however none of the 
monkeys had received drug discrimination training 
prior to this experiment. For each animal, at least 6 
months intervened between previous experiments and 
the beginning of this study. 
Appurutus 
Each experimental chamber was equipped with two 
response levers (model PRL-OOI/‘121-07. BRS-LVE, 
Beltsville, MD) mounted about 1Ocm apart and 
equidistant from a food receptacle. The levers and 
food receptacle were mounted approx. 50cm above 
the floor of the chamber and were within easy reach 
of the monkey. The chamber was ventilated by an 
exhaust fan. and a loudspeaker mounted inside the 
chamber provided continuous white masking noise. 
An array of colored 7-W bulbs (model C7-CC. Gen- 
eral Electric Co.. St Louis. MO) was mounted at the 
top of the front wall inside the chamber. Banana- 
flavored food pellets (300 mg, Formula G. P. J. Noyes 
Co.. Lancaster, NH) were delivered to the food recep- 
tacle by a pellet dispenser (Model A. Ralph Ger- 
brands Co., Arlington. MA) mounted outside the 
chamber. Programming. recording and data collec- 
tion were accomplished with a computer (Model 
960A. Texas Instruments Co.. Dallas, TX) and cumu- 
lative recorders (Model C-3. Ralph Gerbrands Co.). 
The procedure has been described previously (Ber- 
talmio. Herling, Hampton, Winger and Woods, 1982). 
Before each daily session. each monkey was removed 
from its home cage and placed in a primate restrain- 
ing chair. Monkey and chair were then placed in the 
experimental chamber and the monkey was given 
either a subcutaneous injection of 1.X mg/kg of 
ketamine or a control injection. After a IO min black- 
out. two blue lights inside the chamber were illumin- 
ated and each press of the lever designated as correct 
for the session resulted in the delivery of a food pellet. 
The designation of “correctness” depended on the 
injection given prior to the session; e.g. the right lever 
after ketamine and the left lever after control. Train- 
ing sessions were conducted 6 days per week with 
ketamine and control injections alternating daily. 
The response requirement was increased through- 
out the sessions to 100 consecutive responses. When a 
monkey emitted a minimum of 90”,, correct responses 
for five consecutive sessions. the final phase of train- 
ing was initiated. Daily sessions consisted of a series 
of 5 min trials separated by 10 min blackout periods. 
Immediately before each blackout period, the monkey 
was given either a control injection or a subcutaneous 
injection of 1.8 mg/kg of ketamine. After 10 min. the 
trial began and completion of 100 consecutive re- 
sponses on the correct lever resulted in the delivery of 
3 g of food. Responses on the incorrect lever reset the 
response requirement on the correct level to 100. At 
the end of 5 min. whether food had been delivered or 
not, the trial ended and the monkey received the next 
injection. 10min prior to the start of the next trial, 
Thus. the time between successive injections was con- 
stant (i.e. 15 min). irrespective of the rate of rcspond- 
ing in a particular trial. 
Each training session began with from zero to four 
control trials and ended with two drug trials, The 
number of control trials was varied from day to day 
to prevent the detection of the drug trials on the basis 
of the number of preceding control trials. All control appropriate responding by the mean dose of each 
trials were preceded by control injections. but only compound (pmol/kg) which produced the same effect. 
the first of the two drug trials was preceded by an At each dose of all compounds tested. the rates at 
injection of ketamine. The second drug trial was pre- which responses were emitted, irrespective of the lever 
ceded by a control injection. since ketamine was on which they occurred, were calculated in responses/ 
assumed to be present from the first drug trial. A sec. 
discrimination was considered to be established when 
a monkey emitted a minimum of 90”” correct re- Drugs 
sponses in each trial for five consecutive sessions. The drugs used in this experiment were ketamine 
During this phase of discrimination training. it was hydrochloride (Warner-Lambert, Ann Arbor, MI). 
necessary to decrease the training dose of ketamine to phencyclidine hydrochloride. I-phenylcyclohexyl- 
1 .O mg/kg for one monkey (808). as this animal con- amine hydrochloride. N-methyl-, N-ethyl-. N-pro- 
sistently did not complete the response requirement pyl-, N-butyl-, N-isopropyl-, N-src-butyl-. N,N- 
following the injection of 1.8 mg/kg of ketamine. The dimethyl-, and N-N-diethyl-l-phenylcyclohexylamine 
smaller training dose in this monkey and the original hydrochloride (provided by Dr Robert E. Willette. 
training dose in the other two monkeys were main- National Institute on Drug Abuse. Bethesda. MD), 
tained throughout the remainder of the experiment. N-allyl-I-phenylcyclohexylamine hydrochloride (pro- 
Testing procedure 
vided by Dr Asher Kalir. Israel Institute of Biological 
Research, Ness-Ziona, Israel), d-amphetamine sulfate 
Test sessions were identical to training sessions. (Sigma Chemical Co.. St Louis. MO). atropine sulfate 
except that in each trial 100 consecutive responses on (Ruger Chemical Co., Irvington. NJ). chlorpromazine 
the lever appropriate for either control injections or hydrochloride (Smith Kline & French Laboratories. 
ketamine injections resulted in the delivery of food, Philadelphia, PA). codeine phosphate (S.B. Penick & 
and each trial was preceded by a subcutaneous injec- Co.. Lyndhurst, NJ), diazepam (base) (Hoffmann-La 
tion of the test drug which increased the total dose Roche. Inc., Nutley. NJ) and quipazine maleate (Miles 
injected within the session by l/4 or l/2 log-unit steps. Laboratories. Elkhart. IN). Diazepam was dissolved 
In general. a test session continued until the monkey in a solution containing 4OY, propylene glycol. IO”, 
made at least 90% of its responses in two successive ethanol, 5”~” sodium benzoate and benzoic acid, 1.5”” 
trials on the lever appropriate for ketamine or until benzyl alcohol and 43.5”)” sterile water. The remainder 
responding in two successive trials was markedly sup- of the drugs were dissolved in sterile 0.9”,, sodium 
pressed. If food reinforcement was not obtained in a chloride. Doses are expressed as the forms described 
trial at a given dose of a test compound (i.e. if the above. 
monkey did not emit 100 consecutive responses on 
either the control- or ketamine-appropriate lever), the 
following trial was preceded by a control injection. 
RESULTS 
and the data from both trials were averaged in ana- 
lyzmg the effects of that dose of the test compound. Discriminations were established with ketamine in 
Training and test sessions were conducted in alter- each monkey. The number of training sessions 
nation 6 days per week. If a monkey failed to exhibit required until criterion performance was attained in 
criterion performance in a training session (i.e. at least each animal was 48, 51 and 52. In training sessions, 
907, correct responses in each trial), testing sessions the rate of lever-press responding in trials that were 
were not conducted until criterion performance was preceded by control injections ranged between 2.0 
attained in two consecutive training sessions. and 4.0 responses/set. Response rates decreased to 
Duta analyses 
between 0.1 and 2.5 responses/set in the first of the 
two trials that followed injections of ketamine. In the 
The data on the discriminative control of behavior second of these trials, response rates approximated 
exerted by each dose of the test compounds were cal- those which followed control injections. Throughout 
culated as the mean percentage of ketamine-appro- the course of these experiments, which were con- 
priate responses + 1 SEM. If the rate of lever-press ducted over approximately 1 year, there was no 
responding by an individual monkey at a dose of a apparent development of tolerance to the response 
test compound was less than 0.1 responses/set, the rate-decreasing effects of ketamine. In addition, each 
percentage of ketamine-appropriate responses emitted animal consistently performed at or above criterion 
by that monkey at that dose was not included in the levels during the training sessions that were inter- 
calculations. For each compound which produced posed between dose-response determinations of test 
dose-related ketamine-appropriate responding, the compounds. Occasional substitution of saline injec- 
smallest dose tested that produced maximum tions for control injections. as well as tests with saline, 
ketamine-appropriate responding was calculated as a produced only control-appropriate responding. 
mean k 1 SEM. Potencies compared to phencyclidine In tests of stimulus generalization, the smallest dose 
were obtained by dividing the mean dose of phencyc- of ketamine (0.1 mg/kg) produced only control-appro- 
lidine (pmol,kg) which produced maximum ketamme- _ nriate resoonding (Fig. 1, unner left nanel). Increasing . _ _ . I _ 
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Fig. 1. Cumulative dose-response curves of the discriminative control of behavior exerted by phencyc- 
lidine and ketamine (upper left panel) and by six drugs that failed to produce stimulus control of 
behavior similar to that of ketamine (upper right panel) in rhesus monkeys trained to discriminate 
subcutaneous injections of ketamine from control injections. and the effects of these drugs on the rate of 
lever-press responding (lower panels). The upper panel ordinates indicate the average number of re- 
sponses emitted on the ketamine-appropriate lever. expressed as a percentage of the total trial responses. 
The lower panel ordinates indicate the average rate of responding after injection of drug expressed m 
responsessec. The abscissae indicate the cumulative doses of the drugs. in milligrams per kilogram. 
Vertical lines through the points indicate f 1 SEM. 
cumulative doses of ketamine produced a dose-related mately six-times more potent than ketamine. Both 
increase in the percentage of total responses emitted ketamine and phencyclidine produced decreases in 
on the ketamine-appropriate lever that reached 90”, the rate of lever-press responding at doses that pro- 
or greater in each of the monkeys at 1.8 and duced 909; or greater ketamine-appropriate respond- 
3.2 mg/kg (Fig. 1. upper left panel). Phencyclidine also ing (Fig. 1, lower left panel). Larger doses of both 
produced dose-related ketamine-appropriate respond- drugs eliminated responding. and ataxia. excessive 
ing which was greater than 90”” at 0.32 mg/kg (Fig. 1. salivation and nystagmus were noted in each monkey 
upper left panel). Thus, phencyclidine was approxi- at these doses, In contrast to ketamine and phencyc- 
Table 1. Chemical structures of N-substituted analogs of phencyclidine 
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Table 2. Results of tests with phencyclidine (PCP) and N-substitued analogs of 
phencyclidine 
Maximum 
Dose range ketamine- 
tested appropriate 

































91.7 i_ 6.5 
93.0 + 7.0 
16.7 ; 23.3 
17.3 + 17.7 
80.7 + 12.4 
96.3 + 2.3 
96.0 + 4.0 
75.0 + 17.7 
90.3 _t 6.0 
61.7 & 34.8 
94.3 + 5.7 
0.37 & 0.00 
4.33 + I.55 
1.53 z 0.33 
0.27 * 0.06 
0.50 * 0.1’ 
0.87 f 0.16 
1.03 f 0.53 
0.30 + 0.00 
0.60 + 0.00 
2.00 f 0.78 
0.71 + 0.18 
1.08 * 0.14 
I.52 + 0.x3 
1.86 f 0.56 
2.29 + 0.25 
1.71 7 0.51 
3.14 * 0.21 
2.38 + 0.43 
1.40 i 0.61 
1.43 + 0.77 
1.58 * 0.29 
2.02 f I.06 
* Percentage of total (k I SEM) based on the average of dose-effect curves deter- 
mined in three monkeys. 
t Average cumulative dose (m&kg _+ 1 SEM) that produced maximum ketamine- 
appropriate responding. 
$ Average rate of responding (responses/set k I SEM) at doses that produced maxi- 
mum ketamine-appropriate responding. 
lidine. quipazine, atropine, d-amphetamine. chlorpro- 
mazine, codeine and diazepam produced exclusively 
control-appropriate responding in each monkey at all 
doses tested (Fig. 1. upper right panel). which in- 
cluded doses that markedly reduced response rates 
(Fig. 1, lower right panel). 
Each of the N-substituted analogs of phencyclidine 
tested in this experiment (Table 1) produced effects 
that were similar to the effects produced by ketamine 
and phencyclidine. The dose range of each compound 
that was tested is shown in Table 2. Following the 
smallest dose of each analog, responding occurred ex- 
clusively on the control-appropriate lever. As the dose 
of each compound was increased. there was a con- 
comitant increase in the percentage of total responses 
that were emitted on the ketamine-appropriate lever. 
The average maximum ketamine-appropriate re- 
sponding produced by each analog varied from 62.7 
to 96.3”;) (Table 2). However. each of the analogs pro- 
duced greater than 75”, ketamine-appropriate re- 
sponding at one or more doses in at least two of the 
monkeys. In the instances where the average maxi- 
mum amount of ketamine-appropriate responding 
was less than 90?, (e.g. compound IX. PCDMA: 
Table 2). the large standard errors reflect the fact that 
two monkeys responded almost exclusively on the 
ketamine-appropriate lever at one or more doses, 
while the third did not. The average rates of respond- 
ing at the doses of each analog that produced maxi- 
mum ketamine-appropriate responding are shown in 
Table 2. At the largest dose of each analog, response 
rates were decreased considerably. and ataxia, exces- 
sive salivation and nystagmus were observed. There 
was an approx. 20-fold difference in potency between 
the least potent (i.e. compound 1, PCA) and the most 
potent (i.e. compound III, NEPCA; Table 2) of the 
N-substituted analogs of phencyclidine. The N-ethyl 
analog (NEPCA) produced maximum ketamine- 
appropriate responding at a mean dose of 0.27 mg/kg 
(Table 2) and was thus slightly more potent than 
phencyclidine. On a pmol/kg basis, however. this 
compound was approximately equipotent with phen- 
cyclidine (Table 3). 
Compounds ILV form an homologous series of 
N-substituted analogs of phencyclidine with increas- 
ing length of the single. saturated, unbranched. 
N-alkyl chain. The most potent compound in this 
series was N-ethyl-1-phenylcyclohexylamine (Table 2. 
compound III. NEPCA). There was an orderly de- 
crease m potency as the N-alkyl chain was increased 
or decreased from two carbons in length (Table 2). 
The only analog of phencyclidine that contained an 
unsaturated N-alkyl chain (compound VI, NAPCA) 
was approximately one-half as potent as its saturated 
counterpart (compound IV. NPPCA; Table 2). Both 
of the analogs which contained branched N-alkyl 
chains (compounds VII and VIII) were somewhat 
more potent than their respective straight-chain 
isomers (compounds IV and V; Table 2). Finally, two 
NJ-dialkyl analogs (compounds IX and X) were 
somewhat less potent than their respective monoalkyl 
counterparts (compounds II and III: Table 2). The 
NJ-diethyl analog (compound X, PCDEA). which 
differs from phencyclidine only by the lack of a single 
methylene group between the two N-alkyl chains, was 
about one-half as potent as phencyclidine. 
DISCUSSION 
Rhesus monkeys trained to discriminate ketamine 
from control injections generalized completely to 
phencyclidine, which was approximately six-times 
more potent than ketamine in producing dose-related 
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Table 3. Potencies of N-substituted analogs of phencychdine compared to phencyc- 
lidine using different assays 
(A) (D) 
Rhesus (B) Displacement of 
monkey Rat (C) [‘H]PCP from 
dlscriminatlve discriminative Mouse rat brain 





















I .oo: I .oo I.00 
I.02 4.96 I.84 
0.Y7 2.59 NT;; 
0.58 0.9’) 0.74 
0.5 I 0.56 0.28 
0.43 0.79 0.37 
0.35 0.39 0.37 
0.28 NT NT 
0.17 0.82 0.82 
0.14 0.51 NT 
0.06 0.45 0.71 
Co~fi~&t.\ of correlution 
or70 
d.f. p II 
A vs B 8 < 0.015 
A vs C 0.75 6 < 0.025 
A vs D 0.53 8 NS 
B vs C 0.91 6 < 0.0025 
BvsD PO.08 8 NS 












* Jasinski et (11. (1981). In: Phencyclidine (PCP): Cwmt md Historicul Pmpctiws 
(Domino. E. F.. Ed.). pp. 331-400. Ann Arbor. NPP Books. 
t Shannon (1981) J. Phurmuc. r\-p. Thrr. 216: 543-551. 
$ pmol of PCP equivalent to I gmol of listed compound. 
3 Not tested. 
One-tailed test for significant deviation from the normal distribution (null hypoth- 
esii: r = 0) 
ketamine-appropriate responding. These results are 
consistent with numerous previous reports of the dis- 
criminative stimulus effects of these drugs in other 
species (e.g. Holtzman. 1980; Shannon. 1981; Herling 
ct (I/., 1981; Brady and Balster, 1981). The subjective 
syndrome produced by phencyclidine. which includes 
disorientation. drunkenness. and psychotomimetic 
effects (e.g. Luby er ~1.. 1959), is also produced by 
ketamine (Domino et ~1.. 1965). Thus, the results of 
this experiment are consistent with the supposition 
that drug generalization studies are appropriate for 
assessing similarities in the subjective effects produced 
by drugs in man (e.g. Holtzman. Shannon and 
Schaefer. 1977). 
In contrast to ketamine and phencyclidine only 
control-appropriate responding was produced by 
d-amphetamine. atropine, chlorpromazine. codeine, 
diazepam and quipazine, although each drug was 
tested at doses up to and including those which were 
behaviorally active. The pharmacological specificity 
of the discriminative stimulus effects of ketamine and 
phencyclidine in rhesus monkeys is in general agree- 
ment with previous reports of the specificity of phen- 
cyclidine-like discriminative stimuli in other species, 
in that barbiturates, cannabinols. hallucinogens, cer- 
tain narcotics and agonists or antagonists of 
dopaminergic. serotonergic or cholinergic systems do 
not substitute for phencyclidine (Jiirbe et ul., 1975; 
Overton, 1975; Poling et ctl., 1979; Shannon. 1981). 
Thus. data from this and previous experiments indi- 
cate that the discriminative stimulus effects produced 
by phencyclidine are representative of a unique class 
of drugs. 
The N-substituted analogs of phencyclidine tested 
in the present experiment were similar to phencyc- 
lidine in that each produced dose-related ketamine- 
appropriate responding. Thus, there do not appear to 
be strict structural requirements in the region of the 
piperidine moiety of phencyclidine for producing 
phencyclidine-like behavioral effects in rhesus mon- 
keys. These results are consistent with previously 
reported data on the phencyclidine-like discriminative 
stimulus effects of many of these analogs in rats 
(Shannon, 1981). 
In contrast to the qualitative similarity between the 
effects produced by phencyclidine and a number of its 
N-substituted analogs. there were large differences in 
the doses at which these compounds produced 
ketamine-appropriate responding. In the absence of 
extensive pharmacodynamic or pharmacokinetic data 
on a series of N-substituted analogs of phencyclidine, 
the variations in potency which resulted from small 
structural differences among these compounds suggest 
certain characteristics of the putative phencyclidine 
receptor (Vincent er nl., 1979; Zukin and Zukin, 1979). 
The N-ethyl analog was the most potent among an 
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homologous series of primary amines and potency de- 
creased in an orderly fashion as the length of the 
N-substituted alkyl chain was altered by substituting 
either different primary N-alkyl groups or N-alkyl 
groups that contained a secondary carbon. These 
results suggest that the putative phencyclidine recep- 
tor may contain a site which interacts most readily 
with a two-carbon hydrophobic substituent at the 
nitrogen atom of these compounds. In addition, the 
decrease in potency observed upon replacing the satu- 
rated N-alkyl chain of one of these analogs (NPPCA) 
by its unsaturated counterpart (NAPCA) further im- 
plies that this region of the putative phencyclidine 
receptor may be relatively lipophilic in character. 
Finally, the greater potency of phencyclidine com- 
pared to its N,N-diethyl analog (PCDEA) suggests 
that the planar. rigid piperidine moiety confers a 
greater affinity for the receptor than do similar. non- 
rigid, N-alkyl substititutions. Thus, the area of the 
phencyclidine receptor site with which the nitrogen 
pharmacophore interacts appears to be relatively flat. 
The phencyclidine-like behavioral effects of several 
N-substituted analogs in rodents and their potencies 
in displacing [3H]phencyclidine from membranes of 
rat brain were studied by Jasinski et a[. (1981). The 
potencies of these compounds compared to phencyc- 
lidine are shown in Table 3. as are their relative 
potencies as determined in the present experiment. 
Only the relative potencies of these compounds in 
producing behavioral effects are significantly corre- 
lated. While the order of potencies within certain sub- 
groups of these analogs were often similar in rhesus 
monkeys and in rodents (e.g. NEPCA was the most 
potent analog in each of the behavioral assays), cer- 
tain analogs were more potent than phencyclidine in 
rodents. whereas none of the compounds was more 
potent than phencyclidine in rhesus monkeys. Simi- 
larly, NEPCA has been found to be two- to six-times 
more potent than phencychdine in disrupting forced 
motor performance in mice (Kalir. Edery. Pelah. Bal- 
derman and Porath. 1969: Kalir, Maayani. Rehavi. 
Elkavets. Pri-Bar. Buchman and Sokolovsky. 1978; 
Balster. 1980) and in affecting avoidance responding 
in rats (Shannon and DeGregorio. 1981). whereas in 
monkeys this compound is less potent than phencyc- 
hdine in producing catelepsy (Chen. 1965). character- 
istic changes in the spontaneous EEG (Gehrmann 
and Killam. 1979). effects on fixed-interval perform- 
ance (Brady, Balster, Meltzer and Schwertz. 1980) and 
phencyclidine-like discriminative effects (Brady and 
Balster. 1981). Thus, despite the significant corre- 
lations between the relative potencies of these com- 
pounds in producing behavioral effects in rodent and 
primate species. there is considerable evidence for spe- 
cies differences in structureeactivity relationships at 
the nitrogen pharmacophore of phencyclidine. 
These results may be due to species differences in 
the distribution or biotransformation of these com- 
pounds. For example, NEPCA has been found to 
enter the brain to a greater extent than phencyclidine 
following systemic administration in mice (Kalir c’t crl.. 
1978). For the lack of comparable data in primates. 
however. the suggestion that this finding may account 
for the greater potency of NEPCA compared to phen- 
cyclidine in rodents in comparison to the relative 
potencies of these two compounds in primates (Brady 
and Balster. 1981) remains only a possibility. On the 
other hand. there may be differences between rodents 
and primates in the physiochemical characteristics of 
the putative phencyclidine receptor site. Further data 
are necessary to determine which of these mechanisms 
might account for the observed species differences. 
It is interesting to note that the relative potencies of 
phencyclidine and its N-substituted analogs in pro- 
ducing behavioral effects in rhesus monkeys or in 
rodents were not well correlated with their relative 
potencies in displacing [ 3H]phencyclidine from mem- 
branes of rat brain (Table 3). Differences between the 
relative intrinsic affinities and intrinsic activities of 
these compounds may account for these results (see 
Jasinski et a/., 1981 for discussion). However, the 
procedure used to measure the displacement of mem- 
brane-bound [3H]phencyclidine by Jasinski et al. 
(1981) has been shown to be confounded by the dis- 
placement of phencyclidine from glass fiber filters 
(Maayani and Weinstein, 1980). It has recently been 
shown that the interference with displaceable binding 
of [3H]phencyclidine by glass filters is markedly 
reduced by pre-soaking the filters in polyethylene- 
imine (Hampton et ul., 1980, 1982) or polylysine 
(Zukin and Zukin, 1981). Displaceable binding of 
C3H]phencyclidine to membranes of rat and pigeon 
brain, studied with this method, exhibits stereoselec- 
tivity (Hampton rt a/., 1980, 1982) consistent with that 
demonstrated for producing discriminative stimuli 
similar to those of phencyclidine and ketamine in 
pigeons (unpublished observations). Comparable 
binding data on a series of N-substituted analogs 
of phencyclidine. however. have not yet been 
reported. 
In conclusion. the present data support the hypoth- 
esis that substitution of various N-alkyl groups for 
the piperidine moiety of phencyclidine alters the 
potency, but not the characteristic pharmacological 
activity. of the resulting compounds (Jasinski ef (I/.. 
1981). Thus. the suggestion that certain of these ana- 
logs may be abused for their phencyclidine-like effects 
(Shulgin and MacLean. 1976) is supported by the 
present findings, and implies that strict control of 
phencyclidine alone is not likely to prevent the abuse 
of phencyclidine. Additionally, the structure-activity 
relationships observed between N-substituted analogs 
of phencyclidine in rhesus monkeys suggest the pres- 
ence of a flat, lipophilic area at the active site of the 
putative phencyclidine receptor with which the nitro- 
gen pharmacophore of these compounds may inter- 
act. Finally, the present data provide further evidence 
for differences between rodents and primates in struc- 
ture-activity relationships between phencyclidine and 
its N-substituted analogs. 
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